Drug · Monoclonal Antibody

Pertuzumab

CI-DRUG-00000470Explore in graph →NCIt C38692 CHEMBL2007641 CIViC Approved

Regulatory

Approvals (17)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory17 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as PHESGO (DIN 02512920) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 9, 2021	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	104	43	62	230	17	CA, EU, US	Jun 8, 2012	2001-11
Malignant Breast Neoplasm	Approved	Phase 4	70	26	39	152	6	EU, US	Jun 8, 2012	2003-02
Malignant Colon Neoplasm	Phase3	Phase 3	2	1	1	4	0	—	—	2007-10
Malignant Esophageal Neoplasm	Phase3	Phase 3	2	1	1	2	0

Curated evidence

Clinical evidence (24)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–24 of 24 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification12
Pertuzumab + Trastuzumab

Clinical trials

Trials with this intervention (239)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 239 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02390427	Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer	completed	Phase 1	68	Nancy Lin, MDOTHER	1	Sep 24, 2026	clinicaltrials
NCT03716180	DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC	active not recruiting	Phase 1

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor
Targets: 1 gene
UNII: K16AIQ8CTM
Aliases: 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Omnitarg perjeta, Perjeta, PERJETA, PERJETA-HERCEPTIN, Pertuzumab, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Pertuzumab component of phesgo, Pertuzumab-dpzb, Pertuzumab-zzxf, PHESGO, Poherdy, RG-1273, Rhumab 2C4, RhuMAb2C4, RHUMAB 2C4, RHUMAB2C4 … (+6)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (14)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FD02	PERTUZUMAB
ATC (WHO)

ERBB3 EXPRESSION2
Pertuzumab	Melanoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID3051 A preclinical study demonstrating that in a subgroup of BRAF/NRAS wildtype/wildtype showing high levels of phospho-ErbB3, knockdown of NRG1 reduced viability and decreased activation of ErbB3, ErbB2 a… (full text at CIViC) PMID 26206558 · Capparelli et al., 2015 · Open in CIViC	civic
9F7-F11 + PertuzumabCombination	Pancreatic Ductal Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID865 In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC) PMID 25216528 · Thomas et al., 2014 · Open in CIViC	civic